January 14, 2020

FierceBiotech Executive Breakfast & Panel Discussions at J.P. Morgan 2020

The Fairmont | Grand Ballroom | San Francisco

About

Join FierceBiotech during the J.P Morgan Healthcare Conference with a full breakfast, two panel discussions, and networking at The Fairmont in San Francisco.

Attendees will have the opportunity to engage with speakers and panelists, expand their knowledge on the biotech and healthcare industries, and network with peers and colleagues.

Event Schedule:
7:00AM-7:45AM // Registration, Breakfast Buffet, and Networking
7:45AM-9:15AM // Panel One - Strategic Considerations for the Commercialization of Cell and Gene Therapies
9:15AM-9:45AM // Coffee Break and Networking
9:45AM-11:00AM // Panel Two - The Promise of AI: Can Artificial Intelligence and Machine Learning Really Transform R&D?
11:00AM-11:30AM // Ask the Experts Closing Reception, Sponsored By: Clarivate Analytics

View panel and speaker information below.

Speakers

Dr. Mitchell (Mitch) Finer

Chief Scientific Officer / ElevateBio
Dr. Mitch Finer is the Chief Scientific Officer of ElevateBio and the President of ElevateBio BaseCamp. For three decades, Mitch has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, and he has held several senior leadership roles in companies developing these therapies. Dr. Finer received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley.

Chris Gibson, Ph.D.

Co-Founder and CEO / Recursion Pharmaceuticals
Chris Gibson, Ph.D., is Co-Founder and CEO of Recursion Pharmaceuticals, a clinical-stage biopharma company leveraging the latest in automation, artificial intelligence, biology and chemistry to discover new medicines at scale. Chris is a graduate of Rice University with degrees in bioengineering and managerial studies, as well as a Ph.D. from the University of Utah training with Recursion co-founder Dean Y. Li, MD/PhD. Chris is a Board Member of CureHHT, and a member of the Rare and Undiagnosed Network Advisory Board. 

Kevin Julian

Senior Managing Director, Life Sciences / Accenture
Kevin Julian is a senior managing director leading Accenture's global Applied Life Sciences Solutions practice. He is responsible for industry-specific solutions and platforms that leverage Accenture’s expertise in strategy, consulting, technology, digital and operations – helping life sciences clients bring innovative products to patients faster.

A Systems Engineering graduate of the University of Pennsylvania, Kevin has worked predominantly in life sciences for 30 years, delivering leading-edge solutions and complex programs to help clients improve business performance.

Daphne Koller

CEO and Founder / Insitro
Daphne Koller is CEO and Founder of Insitro, a company applying machine learning to drug development. Daphne was a Computer Science Professor at Stanford, co-founder and co-CEO of Coursera, and Chief Computing Officer of Calico. Daphne was one of TIME Magazine’s 100 most influential people and is a MacArthur Fellow, a member of the National Academy of Engineering, and a Fellow of the American Academy of Arts and Sciences and the International Society of Computational Biology. 

David J. Lennon, Ph.D.

President / AveXis, a Novartis Company
Dave Lennon is President of AveXis, a Novartis company. He leads the organization in its mission to bring gene therapy to patients and families devastated by rare and life-threatening neurological genetic diseases.

Dave has served in a number of global leadership roles with Novartis since 2005 and was previously with McKinsey & Company.
Dave holds a B.A. in biophysics from Columbia University and a Ph.D. in cell biology from Weill Medical College at Cornell University.

Paul Levesque

Global President of Pfizer Rare Disease / Pfizer
Paul Lévesque is the Global President of Pfizer Rare Disease. He has successfully driven growth while serving a broad range of General Management roles across diverse therapeutic areas and geographies including: Asia Pacific/China, Europe, and USA/Canada. He also led the Pfizer Zika Project addressing a public healthcare emergency. Paul holds a BSc in biochemistry from Laval University, Quebec City, and a Diploma in Management from McGill University, Montreal. 

Christopher McKenna

Global Head of Professional Services & Consulting / Clarivate Analytics
Chris McKenna has 30 years of wide-ranging experience working in the pharma and biotech industries including the development of drug discovery models, biological screening solutions, business development and licensing in asthma, RA, skin, Diabetes, and R&D informatics implementation.  Chris joined Clarivate Analytics in 2011, successfully leading the global commercial launch of Cortellis and the Professional Services business.  He now manages the Discovery & Translational Science and Data Science practices leading many AI initiatives and is currently researching new AI approaches for Business Development and Licensing teams.

Melanie Nallicheri

Life Sciences Executive, Former Chief Business Officer and Head / Biopharma, Foundation Medicine; Former SVP, Corporate Strategy and Business Development / McKesson

Melanie Nallicheri has more than 25 years of life sciences and healthcare industry expertise spanning corporate strategy, operational execution and finance. Most recently, she served as Chief Business Officer and Head, Biopharma for Foundation Medicine, where she was responsible for architecting and directing the company's growth initiatives, while driving demonstrable expansion of the company's biopharma collaborations. 

Keiko Oishi

President and COO / CMIC
Keiko Oishi is the President and COO of CMIC Group, responsible for group-wide business execution.

Ms. Oishi joined CMIC in 1996 as Manager of Strategy Development. She has since taken on increased responsibilities as Head of International Business and Corporate Development for Asia, CEO of CRO Business and a member of the Board of Directors. Before joining CMIC, she had worked in Nikkei McGraw-Hill, Inc., Genzyme Japan, and Genentech, Japan.

Alberto Santagostino

Head of Cell and Gene Technologies / Lonza
Alberto has a deep knowledge of the manufacturing challenges faced by biopharma, particularly in cell and gene therapies. Together with his team, he supports companies taking their products through the complex journey to commercialization and industrial-scale manufacturing.

Before joining Lonza, Alberto was a Partner at McKinsey & Company leading the Biotechnology service line, as well as the Pharmaceutical and Medical Product practice.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Stephen J. Ubl

President and Chief Executive Officer / PhRMA
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. He is routinely recognized as one of Washington’s most effective advocates, and, in 2018, was named for the third year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare."

Alex Zhavoronkov, PhD

Founder and CEO / Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signalling pathway modelling. 

Amirah Al Idrus

Editor / FierceBiotech
Amirah Al Idrus is an editor with the FierceMarkets Life Sciences group covering medtech and biotech research. Before joining Fierce, Amirah completed a master's degree in journalism at the University of Maryland, where she concentrated in online and multimedia journalism. She has covered issues ranging from Maryland politics and local business to finance in state prisons. When she's not working, Amirah spends her time playing rugby, running around D.C., visiting museums, and baking (and eating) pies. She can be reached at [email protected].

Carly Helfand

Senior Editor / FiercePharma
Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FierceVaccines, FiercePharma and FiercePharmaMarketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfan[email protected].

AGENDA

Strategic Considerations for the Commercialization of Cell and Gene Therapies
7:45AM-9:15AM


Cell and gene therapies have the potential to transform care for a broad range of diseases, but they’re difficult to produce and costly for patients and payers. Companies are building up their manufacturing technology and capacity on one hand while negotiating creative payment arrangements with payers on the other. This panel will discuss the challenges to commercializing cell-based and gene therapies, and explore how drugmakers are leveraging emerging technologies to meet production requirements, maximize efficiency, and track patients’ progress for performance-based payment deals.

  • Gain an overview of the infrastructure required to develop and produce cell and gene therapies, and strategies for scaling up to commercial production.
  • Understand how to demonstrate their value to regulators, payers and physicians.
  • Explore creative economic and commercialization models to reach as many patients as possible.

Keiko Oishi (Opening Remarks)

President and COO / CMIC

Dr. Mitchell (Mitch) Finer

Chief Scientific Officer / ElevateBio

David J. Lennon, Ph.D.

President / AveXis, a Novartis Company

Paul Levesque

Global President of Pfizer Rare Disease / Pfizer

Alberto Santagostino

Head of Cell and Gene Technologies / Lonza

Stephen J. Ubl (Closing Remarks)

President and Chief Executive Officer / PhRMA

Carly Helfand (Moderator)

Senior Editor / FiercePharma

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title
The Promise of AI: Can Artificial Intelligence and Machine Learning Really Transform R&D?
9:45AM-11:00AM


Proponents of high-tech data mining and analysis have been talking up all the buzzwords—AI, machine learning, natural language processing—for years now, but it’s still not clear that these advanced computational tools can live up to the buzz.

Drug discovery, however, is one area where AI systems can actually revolutionize the process. AI and machine learning algorithms can speed up the process of identifying and validating druggable targets, for example. AI can help ferret out compounds worth pulling out of the deep freeze or off the shelf for repurposing. And by applying these tools to patient data—from genomics to electronic health records—researchers can gain deeper insights into the populations they’re ultimately trying to treat.

Can some early successes translate into large-scale transformation of drug research? And can those lessons extend into later phases of drug development, too? This panel will examine those questions and sort out real hope from mere hype.

Chris Gibson, Ph.D.

Co-Founder and CEO / Recursion Pharmaceuticals

Kevin Julian

Senior Managing Director, Life Sciences / Accenture

Daphne Koller

CEO and Founder / Insitro

Christopher McKenna

Global Head of Professional Services & Consulting / Clarivate Analytics

Melanie Nallicheri

Life Sciences Executive, Former Chief Business Officer and Head / Biopharma, Foundation Medicine; Former SVP, Corporate Strategy and Business Development / McKesson

Alex Zhavoronkov, PhD

Founder and CEO / Insilico Medicine

Amirah Al Idrus (Moderator)

Editor / FierceBiotech

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title
Ask the Experts Closing Reception, Sponsored By: Clarivate Analytics
11:00AM-11:30AM

From commercializing cell-based and gene therapies to taking full advantage of Artificial Intelligence and Machine Learning to fuel your deal-making and truly transform your R&D, having the right insights, partners and solutions provides the necessary strategic advantage to get ahead of the competition, get in on and make the right deals and win.  Join featured panelist Chris McKenna and the Clarivate Analytics Experts for a light meal and get your burning questions answered to take the learnings from the panel discussions and more and turn them into a powerful strategy to accelerate your business development and licensing plans.

Light refreshments will be served. 

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

sponsors

Pricing

Registration Rate

Early Bird Rate: $179
[Ends: Friday, December 13]

Standard Rate: $199

location

FAQ

Yes, valet parking is available for an additional fee.

Yes, a full breakfast will be served from 7:00AM-7:45AM

Attendee substitutions may be made on or before January 10, 2020. Please submit a written request by email to [email protected]

Due to the nature of this event, we are unable to provide refunds. Attendee substitutions may be made on or before January 10, 2020. Please submit a written request by email to [email protected]